The Report
Deep dives into company funding, growth strategies, and market insights from the world's most innovative businesses
Modern Meadow transforms biotech industry with $53M Series B at $400M valuation
Modern Meadow achieves $400M valuation through $53M Series B funding, establishing dominance in the biotech market with innovative biotechnology company producing lab-grown leather and meat.
Zymergen transforms synthetic biology industry with $300M Series C at $3.2B valuation
Zymergen achieves $3.2B valuation through $300M Series C funding, establishing dominance in the synthetic biology market with innovative biomanufacturing platform for materials and chemicals.
Ginkgo Bioworks transforms synthetic biology industry with $350M IPO at $15B valuation
Ginkgo Bioworks achieves $15B valuation through $350M IPO funding, establishing dominance in the synthetic biology market with innovative synthetic biology platform for organism design and manufacturing.
BioSynthetic Materials Raises $720M Series D for Revolutionary Synthetic Biology Technology
BioSynthetic Materials secures $720M in Series D funding at $10.8B valuation to pioneer breakthrough synthetic biology technology.
GeneEdit Therapeutics Raises $2.0B Series F for Revolutionary Gene Therapy Technology
GeneEdit Therapeutics secures $2.0B in Series F funding at $29.5B valuation to pioneer breakthrough gene therapy technology.
Twist Bioscience secures $120M Series D for biotech innovation
Twist Bioscience raises $120M in Series D funding to advance its synthetic biology company manufacturing dna sequences and accelerate market growth.
BioSynth Labs raises $380M Series B in September 2025 funding round
BioSynth Labs secures $380M in Series B funding in September 2025, reaching $3.2B valuation to advance its synthetic biology platform for sustainable chemical manufacturing.
EcoMaterials raises $150M Series B in September 2025 funding round
EcoMaterials secures $150M in Series B funding in September 2025, reaching $1.5B valuation to advance its sustainable materials manufacturing using biotechnology.
Illumina transforms genomics industry with $100M IPO at $50B valuation
Illumina achieves $50B valuation through $100M IPO funding, establishing dominance in the genomics market with innovative dna sequencing and array-based technology platform.
Showing 9 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.